Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04690595 · ClinicalTrials.gov registry record · Phase 1
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by PeproMene Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04690595: Active Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by PeproMene Bio.
NCT04690595 is a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by PeproMene Bio. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04690595, a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by PeproMene Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Primary Outcome
Toxicity will be graded per Common Terminology Criteria for Adverse Events version 5.0, Cytokine Release Syndrome (CRS) and neurotoxicity which use the American Society for Transplantation and Cellular Therapy Consensus Criteria (ASTCT) and Graft versus Host Disease (GVHD) criteria. Toxicities will be followed from the start of lymphodepletion until the end of the study.
Conditions Studied
Interventions
- BIOLOGICAL BAFFR-CAR T cells
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2027-11-18 |
| Phase | Phase 1 |
What the registry record for NCT04690595 still lists
NCT04690595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which BAFFR-CAR T cells is the first listed.
NCT04690595 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04690595 about?
NCT04690595 is a clinical study titled "BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL". A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
What is the current status of trial NCT04690595?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-05-18. Estimated completion is 2027-11-18.
What conditions does trial NCT04690595 study?
This clinical trial studies the following conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04690595?
The interventions under investigation include: BAFFR-CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04690595?
This trial is sponsored by PeproMene Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04690595 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04690595's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RECRUITING · Phase 1
-
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI